Guardion Health Sciences, Inc. (NASDAQ:GHSI) Major Shareholder Bradley Louis Radoff Purchases 84,821 Shares of Stock

Guardion Health Sciences, Inc. (NASDAQ:GHSIGet Rating) major shareholder Bradley Louis Radoff bought 84,821 shares of the company’s stock in a transaction that occurred on Monday, January 9th. The shares were bought at an average price of $6.88 per share, with a total value of $583,568.48. Following the completion of the acquisition, the insider now directly owns 186,000 shares in the company, valued at $1,279,680. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Guardion Health Sciences Price Performance

Shares of GHSI stock opened at $7.23 on Thursday. The stock has a market capitalization of $8.91 million, a PE ratio of -9.90 and a beta of 0.89. Guardion Health Sciences, Inc. has a 1-year low of $5.80 and a 1-year high of $33.09. The business has a 50-day moving average of $0.58 and a 200 day moving average of $0.30.

Guardion Health Sciences (NASDAQ:GHSIGet Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.03) EPS for the quarter. The business had revenue of $2.66 million for the quarter. Guardion Health Sciences had a negative net margin of 187.52% and a negative return on equity of 32.56%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Guardion Health Sciences stock. Renaissance Technologies LLC raised its holdings in shares of Guardion Health Sciences, Inc. (NASDAQ:GHSIGet Rating) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,723,950 shares of the company’s stock after purchasing an additional 149,200 shares during the period. Renaissance Technologies LLC owned 2.80% of Guardion Health Sciences worth $238,000 at the end of the most recent reporting period. 16.38% of the stock is owned by hedge funds and other institutional investors.

Guardion Health Sciences Company Profile

(Get Rating)

Guardion Health Sciences, Inc, together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.

Further Reading

Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with's FREE daily email newsletter.